aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2025. All rights reserved.
44 Tehama St, San Francisco, CA 94105
Privacy Policy
aVenture Investment Company ("aVenture") is an independent venture capital research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals.
While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision.
aVenture does not offer investment advisory services and is not registered as an investment adviser. The data provided by aVenture does not constitute recommendations or advice, whether by methodology or a statement written by a staff member of aVenture.
Links to external websites do not imply endorsement or affiliation with aVenture. References or links to providers offering the ability to invest in a primary or secondary transaction in a company are for convenience purposes only. They are not solicitations or offers to buy or sell an investment. Remember that past performance does not guarantee future results, and venture capital and private assets should be a contributory part of a diversified portfolio.
Founded on April 6, 1999, AstraZeneca PLC is a British-Swedish pharmaceutical and biotechnology company headquartered at the Cambridge Biomedical Campus in Cambridge, England. The company focuses on the research, manufacturing, and sales of pharmaceutical and medical products across eight therapeutic areas: gastrointestinal, oncology, cardiovascular, respiratory, central nervous system, pain control, anaesthesia, and infection. AstraZeneca's core mission is to push the boundaries of science to deliver life-changing medicines, with a vision to transform the lives of patients through innovative solutions.
Notable figures associated with AstraZeneca include its leadership team and board members who have driven significant advancements in the pharmaceutical industry. The company has garnered substantial investment from global markets, being publicly traded on multiple stock exchanges including LSE, Nasdaq Stockholm, and Nasdaq. Key achievements include the development of the Oxford-AstraZeneca COVID-19 vaccine, which has had a profound global impact during the pandemic. AstraZeneca continues to influence the healthcare sector through its commitment to scientific excellence and its diverse pipeline of projects aimed at addressing unmet medical needs.
Operating Status
Active
Ownership Type(s)
Public
Main Product(s)
Pharmaceuticals
Technology
Biotech
Tags
Biotech, Healthtech
Model Types
Retail
Revenue Type(s)
Transactional
Customer Type(s)
Consumers, Enterprise
Geographic Exposure
Global
When was AstraZeneca founded?
AstraZeneca was founded in 1999.
Where is AstraZeneca’s headquarters located?
AstraZeneca’s headquarters is located in Redwood City, CA, US.
When was AstraZeneca’s last funding round?
AstraZeneca’s most recent funding round was for $2.3B (USD) in February 2023.
How many employees does AstraZeneca have?
AstraZeneca has 83500 employees as of Feb 6, 2024.
How much has AstraZeneca raised to-date?
As of July 05, 2023, AstraZeneca has raised a total of $3.8B (USD) since Feb 28, 2023.
Add Comparison
Total Raised to Date
$3.8B
USD
Last Update Feb 28, 2023
Last Deal Details
$2.3B
USD
Feb 28, 2023
Post Ipo Debt
Total Employees Over Time
83500
As of Feb 2024
AstraZeneca Address
Redwood City,
California
94065
United States
Source(s): This page includes data and analysis provided by the company, OpenAI, and our research analysts